Vanguard Group Inc. Raises Stock Holdings in IDEAYA Biosciences, Inc. $IDYA

Vanguard Group Inc. raised its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 2.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,019,324 shares of the company’s stock after acquiring an additional 97,116 shares during the period. Vanguard Group Inc. owned approximately 0.06% of IDEAYA Biosciences worth $173,518,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of IDYA. Baker BROS. Advisors LP raised its holdings in shares of IDEAYA Biosciences by 54.6% during the 3rd quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock worth $89,125,000 after acquiring an additional 1,156,716 shares in the last quarter. Millennium Management LLC increased its stake in IDEAYA Biosciences by 345.2% in the first quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock worth $8,970,000 after purchasing an additional 424,625 shares during the period. Balyasny Asset Management L.P. grew its position in shares of IDEAYA Biosciences by 1,619.5% during the 3rd quarter. Balyasny Asset Management L.P. now owns 380,311 shares of the company’s stock worth $10,348,000 after buying an additional 358,194 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of IDEAYA Biosciences by 191.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 497,048 shares of the company’s stock worth $13,525,000 after buying an additional 326,376 shares in the last quarter. Finally, Fiera Capital Corp grew its position in shares of IDEAYA Biosciences by 20.0% during the 3rd quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock worth $50,011,000 after buying an additional 305,698 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Citigroup raised their price objective on IDEAYA Biosciences from $64.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Guggenheim raised their price target on IDEAYA Biosciences from $50.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. The Goldman Sachs Group raised their price target on IDEAYA Biosciences from $31.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, April 14th. Wall Street Zen raised IDEAYA Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Wells Fargo & Company lifted their target price on IDEAYA Biosciences from $44.00 to $48.00 and gave the stock an “overweight” rating in a report on Tuesday, April 14th. Fifteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.69.

Insider Transactions at IDEAYA Biosciences

In related news, Director Jeffrey Stein purchased 50,000 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was bought at an average cost of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the acquisition, the director owned 54,281 shares of the company’s stock, valued at $1,789,101.76. The trade was a 1,167.95% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.70% of the company’s stock.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ:IDYA opened at $28.32 on Monday. IDEAYA Biosciences, Inc. has a 12-month low of $16.84 and a 12-month high of $39.28. The company has a market capitalization of $2.49 billion, a PE ratio of -17.70 and a beta of -0.04. The business has a 50 day moving average of $32.00 and a two-hundred day moving average of $32.96.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. During the same period in the previous year, the firm earned ($0.82) earnings per share. The company’s revenue for the quarter was down 39.4% compared to the same quarter last year. Equities research analysts predict that IDEAYA Biosciences, Inc. will post -4.28 earnings per share for the current fiscal year.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.